NCT06703216View on ClinicalTrials.gov

Pre-emptive Anakinra for Cytokine Event Reduction

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

February 28, 2030

Conditions
B-Acute Lymphoblastic LeukemiaCAR-T Cell TherapyCytokine Release SyndromeImmune Effector Cell Associated Neurotoxicity SyndromeImmune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome
Interventions
DRUG

Anakinra (Kineret®)

Pre-emptive Anakinra at the initial onset of CRS.

Trial Locations (1)

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

All Listed Sponsors
collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

NCT06703216 - Pre-emptive Anakinra for Cytokine Event Reduction | Biotech Hunter | Biotech Hunter